INTERNATIONAL: Thalidomide push from Makovsky to Europe/Australia

WARREN, NJ: Makovsky & Company will spearhead a campaign by

pharmaceutical company Celgene to expand its controversial drug

Thalidomide to European and Australian markets.



Once banned in the US, the drug was given limited FDA approval in 1998

as a treatment for leprosy. More recently, however, it has become known

as an experimental treatment for cancer.



However, the drug faces a tough market in Europe, where during the 1950s

and early 1960s, Thalidomide was prescribed to pregnant women for

morning sickness and as a sleep aid.



More than 10,000 'Thalidomide children' were born, often with extreme

deformities.



Makovksy, Thalidomide's US agency, will manage the international

expansion of the drug through its Australia and London bureaux.



The international offices will report directly to Donna Ramer, MD of

healthcare in Makovsky's New York office.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.